MLN

Summary

MLN (motilin, HGNC:7141) is a protein-coding gene on chromosome 6p21.31, encoding Promotilin (P12872). Plays an important role in the regulation of interdigestive gastrointestinal motility and indirectly causes rhythmic contraction of duodenal and colonic smooth muscle.

This gene encodes a small peptide hormone that is secreted by cells of the small intestine to regulate gastrointestinal contractions and motility. Proteolytic processing of the secreted protein produces the mature peptide and a byproduct referred to as motilin-associated peptide (MAP). Three transcript variants encoding different preproprotein isoforms but the same mature peptide have been found for this gene.

Source: NCBI Gene 4295 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 19 total
• Constraint (gnomAD): pLI 0.02 (LoF-tolerant), LOEUF 1.63 (unconstrained)
• MANE Select transcript: NM_002418

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7141
Approved symbol	MLN
Name	motilin
Location	6p21.31
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000096395
Ensembl biotype	protein_coding
OMIM	158270
Entrez	4295

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

MANE Select: ENST00000430124

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 5: 1

ENST00000430124, ENST00000266003, ENST00000507738, ENST00000960632, ENST00001090880, ENST00001133652

RefSeq mRNA: 3 — MANE Select: NM_002418 NM_001040109, NM_001184698, NM_002418

CCDS: CCDS47412, CCDS4786, CCDS54993

Canonical transcript exons

ENST00000430124 — 5 exons

Exon	Start	End
ENSE00000738724	33799105	33799221
ENSE00000849455	33795503	33795605
ENSE00000849456	33801047	33801170
ENSE00001675754	33794673	33794835
ENSE00001817221	33803953	33804003

Expression profiles

Bgee: expression breadth ubiquitous, 116 present calls, max score 92.54.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2453 / max 128.0077, expressed in 19 samples.

Highest expression (Bgee): duodenum, jejunal mucosa, jejunum, cervix squamous epithelium, diaphragm.

Genetic regulation across tissues (GTEx eQTL / sQTL)

MLN is not an eGene in any GTEx v10 tissue: no tissue shows a variant significantly associated with its expression or splicing (q < 0.05).

FANTOM5 promoters

1 alternative TSS:

Promoter ID	TPM avg	Samples expressed
73192	0.2453	19

Top tissues by expression

showing 100 of 271 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
duodenum	UBERON:0002114	92.54	gold quality
jejunal mucosa	UBERON:0000399	82.85	gold quality
jejunum	UBERON:0002115	76.34	gold quality
cervix squamous epithelium	UBERON:0006922	71.76	gold quality
diaphragm	UBERON:0001103	71.09	gold quality
endometrium epithelium	UBERON:0004811	71.06	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	70.58	gold quality
frontal pole	UBERON:0002795	69.54	gold quality
middle frontal gyrus	UBERON:0002702	69.18	gold quality
paraflocculus	UBERON:0005351	69.13	gold quality
tongue squamous epithelium	UBERON:0006919	68.83	gold quality
epithelial cell of pancreas	CL:0000083	68.30	gold quality
thymus	UBERON:0002370	68.17	gold quality
oocyte	CL:0000023	67.87	gold quality
olfactory bulb	UBERON:0002264	67.20	gold quality
secondary oocyte	CL:0000655	67.12	gold quality
cerebellar vermis	UBERON:0004720	66.52	gold quality
cervix epithelium	UBERON:0004801	65.26	gold quality
Brodmann (1909) area 10	UBERON:0013541	65.01	gold quality
trachea	UBERON:0003126	64.73	gold quality
orbitofrontal cortex	UBERON:0004167	64.35	gold quality
type B pancreatic cell	CL:0000169	63.13	gold quality
pancreatic ductal cell	CL:0002079	63.01	silver quality
nipple	UBERON:0002030	62.69	gold quality
dorsal plus ventral thalamus	UBERON:0001897	62.34	gold quality
pericardium	UBERON:0002407	62.13	gold quality
cardia of stomach	UBERON:0001162	62.10	gold quality
dorsal root ganglion	UBERON:0000044	62.04	gold quality
upper arm skin	UBERON:0004263	62.04	gold quality
pharyngeal mucosa	UBERON:0000355	61.72	gold quality
pylorus	UBERON:0001166	61.71	gold quality
saphenous vein	UBERON:0007318	61.64	gold quality
trigeminal ganglion	UBERON:0001675	61.46	gold quality
synovial joint	UBERON:0002217	61.43	gold quality
ventral tegmental area	UBERON:0002691	61.37	gold quality
tongue	UBERON:0001723	61.33	gold quality
inferior vagus X ganglion	UBERON:0005363	61.32	gold quality
subthalamic nucleus	UBERON:0001906	61.22	gold quality
mucosa of urinary bladder	UBERON:0001259	61.16	gold quality
tibialis anterior	UBERON:0001385	61.08	silver quality
deltoid	UBERON:0001476	61.03	gold quality
pons	UBERON:0000988	61.01	gold quality
substantia nigra pars reticulata	UBERON:0001966	60.95	gold quality
tendon of biceps brachii	UBERON:0008188	60.87	gold quality
superior surface of tongue	UBERON:0007371	60.83	gold quality
renal medulla	UBERON:0000362	60.78	gold quality
body of tongue	UBERON:0011876	60.72	gold quality
quadriceps femoris	UBERON:0001377	60.63	gold quality
trabecular bone tissue	UBERON:0002483	60.63	gold quality
urethra	UBERON:0000057	60.62	gold quality
medulla oblongata	UBERON:0001896	60.49	gold quality
penis	UBERON:0000989	60.42	gold quality
lateral nuclear group of thalamus	UBERON:0002736	60.41	gold quality
lateral globus pallidus	UBERON:0002476	60.35	gold quality
vena cava	UBERON:0004087	60.24	gold quality
substantia nigra pars compacta	UBERON:0001965	60.15	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	60.10	gold quality
squamous epithelium	UBERON:0006914	60.08	gold quality
layer of synovial tissue	UBERON:0007616	59.79	gold quality
superior vestibular nucleus	UBERON:0007227	59.71	gold quality
ileal mucosa	UBERON:0000331	59.58	silver quality
gingival epithelium	UBERON:0001949	59.53	gold quality
decidua	UBERON:0002450	59.11	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	59.07	gold quality
gluteal muscle	UBERON:0002000	59.02	gold quality
triceps brachii	UBERON:0001509	58.91	gold quality
vastus lateralis	UBERON:0001379	58.77	gold quality
cartilage tissue	UBERON:0002418	58.52	gold quality
gingiva	UBERON:0001828	58.51	gold quality
epithelium of mammary gland	UBERON:0003244	58.41	gold quality
amniotic fluid	UBERON:0000173	58.37	gold quality
mammary duct	UBERON:0001765	57.83	gold quality
oviduct epithelium	UBERON:0004804	57.81	gold quality
skeletal muscle tissue	UBERON:0001134	57.57	silver quality
epithelium of esophagus	UBERON:0001976	57.13	gold quality
palpebral conjunctiva	UBERON:0001812	57.08	gold quality
muscle tissue	UBERON:0002385	56.62	gold quality
hair follicle	UBERON:0002073	56.16	gold quality
parietal lobe	UBERON:0001872	55.85	gold quality
biceps brachii	UBERON:0001507	55.69	gold quality
mucosa of sigmoid colon	UBERON:0004993	55.53	gold quality
inferior olivary complex	UBERON:0002127	55.49	gold quality
buccal mucosa cell	CL:0002336	55.24	gold quality
male germ cell	CL:0000015	54.99	gold quality
mammalian vulva	UBERON:0000997	54.85	gold quality
esophagus squamous epithelium	UBERON:0006920	54.80	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	54.79	gold quality
postcentral gyrus	UBERON:0002581	54.68	gold quality
pleura	UBERON:0000977	54.51	gold quality
myocardium	UBERON:0002349	54.22	gold quality
sperm	CL:0000019	53.88	gold quality
parietal pleura	UBERON:0002400	53.75	gold quality
cranial nerve II	UBERON:0000941	53.68	silver quality
small intestine	UBERON:0002108	53.68	gold quality
colonic mucosa	UBERON:0000317	53.66	gold quality
corpus epididymis	UBERON:0004359	53.49	gold quality
oral cavity	UBERON:0000167	53.48	gold quality
entorhinal cortex	UBERON:0002728	53.39	gold quality
visceral pleura	UBERON:0002401	53.38	gold quality
cauda epididymis	UBERON:0004360	52.10	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.98

HPA expression

RNA tissue specificity: Tissue enriched

showing 60 of 83 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Duodenum	tissue	239.2	high
Tongue	tissue	137.2
Skeletal muscle	tissue	117.4
Small intestine	tissue	40.8	high
Retina	tissue	28.2
Cerebellum	tissue	21.6
Pituitary gland	tissue	7.7
Kidney	tissue	7.5
Fallopian tube	tissue	4.8
Pancreas	tissue	2.6
Medulla oblongata	tissue	2.3
Choroid plexus	tissue	2.0
Putamen	tissue	1.9
Thalamus	tissue	1.9
Retrosplenial cortex	tissue	1.9
Pons	tissue	1.6
Hippocampus	tissue	1.6
Basal ganglia	tissue	1.5
Midbrain	tissue	1.5
Substantia nigra	tissue	1.5
Spinal cord	tissue	1.5
Septum	tissue	1.5
Locus coeruleus	tissue	1.4
Olfactory bulb	tissue	1.4
Locus coeruleus	tissue	1.3
Nucleus accumbens	tissue	1.3
Corpus callosum	tissue	1.3
Prostate	tissue	1.2
Entorhinal cortex	tissue	1.2
Esophagus	tissue	1.1
Postcentral gyrus	tissue	1.1
Stomach 1	tissue	1.0
Hypothalamus	tissue	0.9
Postcentral gyrus	tissue	0.8
Duodenum	tissue	0.8
Testis	tissue	0.7
Lung	tissue	0.7
Small intestine	tissue	0.7
Gallbladder	tissue	0.7
Nucleus accumbens	tissue	0.6
Skin 1	tissue	0.6
Cerebral cortex	tissue	0.6
Epididymis	tissue	0.6
Ventral forebrain	tissue	0.6
Retrosplenial and cingulate cortex	tissue	0.6
Appendix	tissue	0.5	not detected
Cervix	tissue	0.5
Endometrium 1	tissue	0.5
Spleen	tissue	0.5
Hippocampal formation	tissue	0.5
Occipital cortex	tissue	0.5
Choroid plexus	tissue	0.4
Hippocampus	tissue	0.4	not detected
Skin 1	tissue	0.3	not detected
Lymph node	tissue	0.3	not detected
Testis	tissue	0.3	not detected
Thymus	tissue	0.3
Retina	tissue	0.2
Adrenal gland	tissue	0.2	not detected
Thymus	tissue	0.2

Brain sub-regions (HPA Brain Atlas): detected in 367; highest nTPM — Cerebellar cortex (10.6), Flocculonodular lobe (9.6), Vermis (9.1), Reticular pontine nucleus, oral (3.2), Nucleus raphe obscurus (2.8).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting MLN by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

3 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1251-3P	99.64	67.21	1408
HSA-MIR-3978	99.24	68.39	2201
HSA-MIR-6774-5P	95.94	65.18	722

Functional genomics

gnomAD constraint: pLI 0.0185, LOEUF 1.63, missense Z -0.145 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000430124 — one region, missense o/e 0.85.

Literature-anchored findings (GeneRIF, showing 12)

• Plasma levels of motilin were studied in 16 untreated Celiac disease patients and in an age-matched control group of 18 healthy subjects by radioimmunoassay and by high-performance liquid chromatography (HPLC). (PMID:12732349)
• Ghrelin and motilin are cosecreted from a prominent endocrine cell population in the small intestine. (PMID:17595255)
• The abnormal excretion of hormonal factors is closely related to gallstone formation (PMID:18234640)
• About 35.9% of the patients with a T tube after cholecystectomy and choledochotomy have duodenal-biliary reflux. Most of them have sphincter of Oddi hypomotility and the decreased level of plasma motilin and serum gastrin. (PMID:18609694)
• Ghrelin covaried with motilin in plasma in irritable bowel syndrome (IBS) but not in plasma from healthy subjects. This suggests the two peptides act together in IBS. (PMID:20338210)
• Motilin may directly influence adipocyte functions by stimulating energy storage. (PMID:21771971)
• Motilin stimulates growth hormone secretion and regulates interdigestive migrating contractions and fasting motor patterns in the gastrointestinal tract. [REVIEW] (PMID:22632857)
• motilin-induced phase III contractions signal hunger in healthy subjects and that this system is disturbed in morbidly obese patients–{REVIEW} (PMID:26660537)
• Serum motilin levels and motilin gene polymorphisms in children with functional constipation. (PMID:27706119)
• Hemodialysis improves upper GI symptoms and gastric slow waves in CKD patients. An increase in ghrelin and a decrease in GLP-1 might be involved in the HD-induced improvement in gastric slow waves. (PMID:28566304)
• Physiological functions and potential clinical applications of motilin. (PMID:36436612)
• Serotonin, ghrelin, and motilin gene/receptor/transporter polymorphisms in childhood functional constipation. (PMID:36888769)

Cross-species orthologs

0 orthologs

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Canis lupus familiaris	P19863	95.5%	Diamond
Felis catus	Q9XSE2	95.5%	Diamond
Macaca mulatta	O18811	93.9%	Diamond
Ovis aries	O18845	92.2%	Diamond
Bos taurus	O62820	92.2%	Diamond
Equus caballus	O46617	80.9%	Diamond
Sus scrofa	P01307	78.1%	Diamond
Oryctolagus cuniculus	P27114	77.5%	Diamond
Cavia porcellus	Q99MP5	72.8%	Diamond
Gallus gallus	Q9PRP6	72.7%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
IP6K3	protein-coding	117283
LEMD2	protein-coding	221496
MIR3934	ncRNA	100500873
UQCC2	protein-coding	84300
LINC01016	ncRNA	100507584

Protein

Protein identifiers

Promotilin — P12872 (reviewed: P12872)

All UniProt accessions (1): P12872

UniProt curated annotations — full annotation on UniProt →

Function. Plays an important role in the regulation of interdigestive gastrointestinal motility and indirectly causes rhythmic contraction of duodenal and colonic smooth muscle.

Subcellular location. Secreted.

Similarity. Belongs to the motilin family.

Isoforms (3)

UniProt ID	Names	Canonical?
P12872-1	1	yes
P12872-2	2
P12872-3	3

RefSeq proteins (3): NP_001035198, NP_001171627, NP_002409* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006737	Motilin_assoc	Domain
IPR006738	Motilin_ghrelin	Domain
IPR015662	Promotilin	Family

Pfam: PF04643, PF04644

UniProt features (9 total): peptide 2, splice variant 2, signal peptide 1, chain 1, region of interest 1, sequence variant 1, helix 1

Structure

Experimental structures (PDB)

2 structures by resolution:

PDB	Title	Method	Resolution (Å)
8IBV	Cryo-EM structure of the motilin-bound motilin receptor-Gq protein complex	ELECTRON MICROSCOPY	3.19
1LBJ	NMR solution structure of motilin in phospholipid bicellar solution	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P12872-F1	68.67	0.08

Antibody-complex structures (SAbDab)

1 antibodies co-crystallized with this protein: 8IBV

Human Protein Atlas

Protein class: Predicted secreted proteins

Protein evidence: Evidence at protein level

Antibody reliability (HPA): IH enhanced

Function

Pathways and Gene Ontology

Reactome pathways

2 curated (TAS) of 7; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

7 pathways:

ID	Pathway	Evidence
R-HSA-416476	G alpha (q) signalling events	curated
R-HSA-375276	Peptide ligand-binding receptors	curated
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)	—
R-HSA-388396	GPCR downstream signalling	—
R-HSA-500792	GPCR ligand binding	—
R-HSA-162582	Signal Transduction	—
R-HSA-372790	Signaling by GPCR	—

MSigDB gene sets: 53 (showing top): MORF_ATRX, MORF_ESR1, BROWNE_HCMV_INFECTION_48HR_DN, REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS, MORF_ETV3, AACTTT_UNKNOWN, MYB_Q3, GOMF_G_PROTEIN_COUPLED_RECEPTOR_BINDING, GOMF_SIGNALING_RECEPTOR_BINDING, MORF_MT4, GCM_LTK, MYB_Q5_01, MORF_MYC, GOMF_HORMONE_ACTIVITY, MORF_PAX7

GO Biological Process (1): signal transduction (GO:0007165)

GO Molecular Function (3): hormone activity (GO:0005179), motilin receptor binding (GO:0031788), protein binding (GO:0005515)

GO Cellular Component (1): extracellular region (GO:0005576)

Reactome top-level categories

5 top-level categories:

Category	Pathways
Signaling by GPCR	2
Class A/1 (Rhodopsin-like receptors)	1
GPCR downstream signalling	1
Signal Transduction	1
GPCR ligand binding	1

GO top-level categories

9 GO namespaces:

Category	Terms
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
receptor ligand activity	1
G protein-coupled receptor binding	1
binding	1
cellular anatomical structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 1 of 5 annotations. The rest are phylogenetic / computational / electronic (IEA).

1 experimentally-supported GO terms:

GO term	NS	Evidence
motilin receptor binding	MF	physical interaction

Protein interactions and networks

STRING

showing 15 of 644 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MLN	MLNR	O43193	988
MLN	GAST	P01350	886
MLN	GHRL	Q9UBU3	836
MLN	PPY	P01298	833
MLN	GHSR	Q92847	828
MLN	SST	P01166	825
MLN	NTS	P30990	824
MLN	CCK	P06307	810
MLN	GPR39	O43194	800
MLN	SCT	P09683	796
MLN	VIP	P01282	779
MLN	TUBB6	Q9BUF5	760
MLN	TUBB8	Q3ZCM7	760
MLN	TUBB4A	P04350	759
MLN	TUBB4B	P05217	758

IntAct

Human interaction partners of MLN in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

2 partners by confidence:

Partner	Interaction type	MIscore	Records
TMX2	physical association	0.560	3
TTC19	physical association	0.560	3

BioGRID (2 interactions; top human partners by supporting records): TMX2 (Two-hybrid), TTC19 (Two-hybrid)

SIGNOR signaling

1 signaling interactions:

A	Effect	B	Mechanism
MLN	up-regulates	MLNR	binding

Disease & clinical

Genetic variants

Variant evidence for MLN: 19 ClinVar records (0 pathogenic / likely pathogenic).

ClinVar

19 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	17
Likely benign	0
Benign	0

AlphaMissense

35 missense substitutions predicted likely pathogenic (of 749 scored), across 19 residues. Top 19 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
F30	5	0.825	0.924
F26	4	0.865	0.937
I29	3	0.712	0.773
P28	3	0.604	0.620
K48	2	0.659	0.659
K5	2	0.605	0.605
Q39	2	0.589	0.589
Q93	2	0.580	0.580
L10	2	0.576	0.583
V27	1	0.732	0.732
T31	1	0.728	0.728
A20	1	0.683	0.683
A16	1	0.673	0.673
R43	1	0.664	0.664
E34	1	0.637	0.637
V13	1	0.626	0.626
L35	1	0.613	0.613
A8	1	0.609	0.609
V12	1	0.603	0.603

HPA cancer prognostics

RNA cancer specificity: Group enriched (Pancreatic Adenocarcinoma, Stomach Adenocarcinoma, Testicular Germ Cell Tumor)

Disease associations

OMIM: gene MIM:158270 | disease phenotypes:

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5214853 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

35 measured of 36 human assays (36 total across all organisms); most potent 35 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CAS_52906-92-0	EC50	0.0398 nM
MOTILIN	EC50	0.15 nM
NSC_0	KI	0.447 nM
[leu13]pMOT(1-19)	KI	0.98 nM
[leu13]pMOT(1-22)	KI	1 nM
[ala3,leu13]pMOT(1-14)	KI	1.32 nM
[leu13]pMOT(1-16)	KI	2.14 nM
[leu13]pMOT(1-14)	KI	3.16 nM
[ala11,leu13]pMOT(1-14)	KI	4.57 nM
[ala10,leu13]pMOT(1-14)	KI	5.01 nM
N-ethyl, N-methyl Erythromycin-A enol ether	KI	6.03 nM
[ala12,leu13]pMOT(1-14)	KI	6.31 nM
[ala14,leu13]pMOT(1-14)	KI	7.08 nM
[ala13,leu13]pMOT(1-14)	KI	7.24 nM
Erythromycin-B enol ether	KI	7.59 nM
[ala5,leu13]pMOT(1-14)	KI	28.8 nM
[ala8,leu13]pMOT(1-14)	KI	36.3 nM
[ala6,leu13]pMOT(1-14)	KI	46.8 nM
[L-Bpa5,Ile13]Motilin	KI	50 nM
ABT-229	KI	58.9 nM
[ala9,leu13]pMOT(1-14)	KI	75.9 nM
[leu13]pMOT(1-11)	KI	89.1 nM
Erythromycin-B	KI	145 nM
Erythromycin-A enol ether	IC50	224 nM
N-ethyl, N-Methyl Erythromycin-A	KI	240 nM
EM-B enolether	KI	324 nM
[D-Bpa5,Ile13]Motilin	KI	420 nM
Erythromycin A Enol Ether	KI	537 nM
[ala7,leu13]pMOT(1-14)	KI	1450 nM
[ala4,leu13]pMOT(1-14)	KI	2570 nM
CAS_114-07-8	KI	3090 nM
[leu13]pMOT(1-9)	KI	4070 nM
[leu13]pMOT(1-7)	KI	6920 nM
[leu13]pMOT(1-5)	KI	8910 nM
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2R,3S,4R,6S)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione	IC50	72400 nM

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.14	Ki	7200	nM	CHEMBL4789678

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression	2
CGP 52608	affects binding, increases reaction	1
bisphenol S	increases methylation	1
Carbamazepine	affects response to substance	1
Triclosan	increases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5214700	Binding	Selectivity interaction (Enzyme panel (ion channels, GPCRs, other targets)) EUB0000196bCl MLN	Selectivity Literature for EUbOPEN Chemogenomics Library wave 3

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for MLN across ~30M SureChEMBL compounds — explore on Sugi Predict.